secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001493152-24-017598
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem reinstates merger with Aditxt after termination, secures $1M payment and new terms
--------------------------------------------------------------------------------

- On May 2, Evofem, Aditxt and merger sub reinstated the merger agreement after termination on April 26.
- Aditxt made a $1M initial payment; must invest up to $2.5M in Series F-1 Preferred via subsequent capital raises by July 1.
- Termination date extended from May 8 to July 15, 2024; no-shop provision eliminated.
- Evofem granted termination rights if $1M not paid by May 3 or interim milestones missed.
- Evofem waived Aditxt's prior non-compliance with initial equity investment obligation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224017598/0001493152-24-017598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224017598/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer